Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Inclusion Criteria

• •Inclusion:
• •1. Signed written informed consent
• •2. AJCC stage 3 or 4 histologically proven NSCLC not amenable to curative therapy and for whom erlotinib and bevacizumab therapy would be appropriate
• •3. Radiological assessment within 21 days prior to inclusion, if measurable disease is present
• •4. Age ≥ 18 years
• •5. ECOG performance status 0 or 1
• •6. Patient has received at least one standard platinum-containing chemotherapy regimen appropriate for his/her lung cancer, in the opinion of the investigator, prior to enrollment.
• •Exclusion:
• •Patients with any of the following will be excluded from participation in the study:
• •Disease
• +38 more criteria